美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Obsidian Therapeutics Inc

19.90

-0.2900-1.44%

盘后：19.900.00000.00%16:10 EDT

成交量：144.93万

成交额：2,913.92万

市值：12.28亿

市盈率：-0.02

高：21.33

开：20.47

低：18.44

收：20.19

52周最高：49.97

52周最低：14.57

股本：6,172.72万

流通股本：5,946.21万

量比：25.28

换手率：2.44%

股息：- -

股息率：- -

每股收益(TTM):-1,287.1293

每股收益(LYR):-2,056.1834

净资产收益率：--

总资产收益率：--

市净率：-4.45

市盈率(LYR):-0.01

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Obsidian Therapeutics Inc

交易所：

NASDAQ

成立时间：

2015

员工人数：

71

公司地址：

1030 Massachusetts Avenue,Cambridge,Massachusetts,United States

官网：

http://www.obsidiantx.com

邮编：

02138

电话：

传真：

- -

简介：

Obsidian Therapeutics, Inc.是一家于2026年4月10日在特拉华州注册成立的生物制药公司。该公司专注于开发小分子超氧化物歧化酶（SOD）模拟物，旨在通过减少副作用来改善癌症放射治疗的效果。Obsidian目前的产品组合包括一种泛NOS抑制剂，其主要研发项目正处于乳腺癌联合治疗的I/II期临床试验阶段。该公司还开发用于治疗实体瘤的工程化肿瘤浸润淋巴细胞（TIL）疗法。Obsidian的专有cytoDRiVE平台能够通过药物响应结构域控制蛋白质功能，初期重点开发基于该平台的TIL细胞疗法。Obsidian的主要候选产品是一种新型的基因工程自体TIL细胞疗法，目前正在进行治疗晚期黑色素瘤和非小细胞肺癌的临床试验。

董事

名称

职位

Madan Jagasia

Chief Executive Officer and Director

Maria Fardis

Chairman of the Board and Director

Heidi Hagen

Director

Matthew Norkunas

Director

Peter Barrett

Director

Robert Ross

Director

股东

名称

职位

Madan Jagasia

Chief Executive Officer and Director

Julie Feder

Chief Financial Officer and Principal Accounting Officer

Dana Alexander

Chief Technical Officer

Parameswaran Hari

Chief Medical Officer

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/OBX/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OBX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OBX\",,,,,undefined,":{"symbol":"OBX","market":"US","secType":"STK","nameCN":"Obsidian Therapeutics Inc","latestPrice":19.9,"timestamp":1787342400000,"preClose":20.19,"halted":0,"volume":1449276,"hourTrading":{"tag":"盘后","latestPrice":19.9,"preClose":19.9,"latestTime":"16:10 EDT","volume":63,"amount":1260.38,"timestamp":1787343004329,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.014363546310054615,"floatShares":59462058,"shares":61727211,"eps":-1287.1293,"marketStatus":"休市中","change":-0.29,"latestTime":"08-21 16:00:00 EDT","open":20.47,"high":21.33,"low":18.44,"amount":29139188,"amplitude":0.14314,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1287.1293,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":20.19,"preHourTrading":{"tag":"盘前","latestPrice":19.49,"preClose":20.19,"latestTime":"04:00 EDT","volume":1,"amount":19.49,"timestamp":1787299213996,"change":-0.7,"changeRate":-0.034671,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":19.9,"preClose":19.9,"latestTime":"16:10 EDT","volume":63,"amount":1260.38,"timestamp":1787343004329,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":25.277246844626724},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OBX\",,,,,undefined,":{"symbol":"OBX","floatShares":59462058,"roa":"--","roe":"--","lyrEps":-2056.183449,"volumeRatio":25.277246844626724,"shares":61727211,"dividePrice":0,"high":21.33,"amplitude":0.14314,"preClose":20.19,"low":18.44,"week52Low":14.57,"pbRate":"-4.45","week52High":49.9699,"institutionHeld":0,"latestPrice":19.9,"eps":-1287.1293,"divideRate":0,"volume":1449276,"delay":0,"ttmEps":-1287.1293,"open":20.47,"prevYearClose":49.9699,"prevWeekClose":17.77,"prevMonthClose":49.9699,"prevQuarterClose":49.9699,"fiveDayClose":17.77},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OBX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-04","symbol":"OBX","defaultRemindTime":1785850200000,"type":"split","dateTimestamp":1785816000000,"forFactor":10000,"toFactor":7019,"ratio":1.4247043738424277}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OBX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OBX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OBX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OBX","date":"2026-08-21","current":-0.015461,"percent":0.444444,"low":-15.919767,"twenty":-13.181567,"median":-9.14022,"eighty":-8.501155,"high":-7.975803,"avg":-10.814753,"sd":2.808659,"marketCap":874758582},"quantilePoints":[{"date":"2026-08-14","current":-8.605771,"twenty":-15.155618,"median":-12.735814,"eighty":-11.727865,"marketCap":819734144},{"date":"2026-08-21","current":-9.183431,"twenty":-13.181567,"median":-9.14022,"eighty":-8.501155,"marketCap":874758582}],"updateTime":1787501687737},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":374941308,"yearFounded":2015,"employeeNum":71,"address":"1030 Massachusetts Avenue,Cambridge,Massachusetts,United States","zipCode":"02138","officePhone":"(781) 806-6245","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://www.obsidiantx.com","stockEarnings":[{"period":"1week","weight":0.1199},{"period":"1month","weight":-0.6018},{"period":"ytd","weight":-0.6018}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.1107},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1229}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Obsidian Therapeutics, Inc.是一家于2026年4月10日在特拉华州注册成立的生物制药公司。该公司专注于开发小分子超氧化物歧化酶（SOD）模拟物，旨在通过减少副作用来改善癌症放射治疗的效果。Obsidian目前的产品组合包括一种泛NOS抑制剂，其主要研发项目正处于乳腺癌联合治疗的I/II期临床试验阶段。该公司还开发用于治疗实体瘤的工程化肿瘤浸润淋巴细胞（TIL）疗法。Obsidian的专有cytoDRiVE平台能够通过药物响应结构域控制蛋白质功能，初期重点开发基于该平台的TIL细胞疗法。Obsidian的主要候选产品是一种新型的基因工程自体TIL细胞疗法，目前正在进行治疗晚期黑色素瘤和非小细胞肺癌的临床试验。","exchange":"NASDAQ","name":"Obsidian Therapeutics Inc","nameEN":"Obsidian Therapeutics Inc"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"OBX\",market:\"US\",,,undefined,":{"directors":[{"name":"Madan Jagasia","position":"Chief Executive Officer and Director"},{"name":"Maria Fardis","position":"Chairman of the Board and Director"},{"name":"Heidi Hagen","position":"Director"},{"name":"Matthew Norkunas","position":"Director"},{"name":"Peter Barrett","position":"Director"},{"name":"Robert Ross","position":"Director"}],"executives":[{"name":"Madan Jagasia","position":"Chief Executive Officer and Director"},{"name":"Julie Feder","position":"Chief Financial Officer and Principal Accounting Officer"},{"name":"Dana Alexander","position":"Chief Technical Officer"},{"name":"Parameswaran Hari","position":"Chief Medical Officer"}]}}}